These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 34293131)

  • 1. Use of a Daratumumab-Specific Immunofixation Assay to Assess Possible Immunotherapy Interference at a Major Cancer Center: Our Experience and Recommendations.
    Kirchhoff DC; Murata K; Thoren KL
    J Appl Lab Med; 2021 Nov; 6(6):1476-1483. PubMed ID: 34293131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distinguishing Drug from Disease by Use of the Hydrashift 2/4 Daratumumab Assay.
    Thoren KL; Pianko MJ; Maakaroun Y; Landgren CO; Ramanathan LV
    J Appl Lab Med; 2019 Mar; 3(5):857-863. PubMed ID: 31639760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Application of Hydrashift 2/4 daratumumab assay in eliminating interference of daratumumab on serum immunofixation electrophoresis].
    Xu S; Liu Y; Wen L; Zhao L; Deng X; Rong R; Lu J
    Zhonghua Xue Ye Xue Za Zhi; 2021 Oct; 42(10):840-845. PubMed ID: 34788924
    [No Abstract]   [Full Text] [Related]  

  • 4. Mitigating the interference of Daratumumab with immunofixation electrophoresis. A single-center experience using Hydrashift 2/4 kit.
    Duek A; Lellouche E; Ben Baruch S; Mashiach R; Segman Y; Bryk G; Leiba M
    Isr Med Assoc J; 2022 Oct; 24(10):629-633. PubMed ID: 36309856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monitoring the M-protein of multiple myeloma patients treated with a combination of monoclonal antibodies: the laboratory solution to eliminate interference.
    Noori S; Verkleij CPM; Zajec M; Langerhorst P; Bosman PWC; de Rijke YB; Zweegman S; VanDuijn M; Luider T; van de Donk NWCJ; Jacobs JFM
    Clin Chem Lab Med; 2021 Nov; 59(12):1963-1971. PubMed ID: 34392637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characteristics of isatuximab-derived interference in serum protein electrophoresis and immunofixation, and an absence of sustained in vivo interference due to belantamab mafodotin and denosumab.
    Jimenez A; Scholl AR; Wang B; Schilke M; Carlsen ED
    Clin Biochem; 2024 May; 127-128():110761. PubMed ID: 38565341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isatuximab-Specific Immunofixation Electrophoresis Assay to Remove Interference in Serum M-Protein Measurement in Patients with Multiple Myeloma.
    Thoren K; Menad S; Nouadje G; Macé S
    J Appl Lab Med; 2024 Jul; 9(4):661-671. PubMed ID: 38573925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluating the HYDRASHIFT 2/4 Daratumumab assay: a powerful approach to assess treatment response in multiple myeloma.
    Lee HW; Kim SM; Park HD
    Clin Chem Lab Med; 2024 Oct; 62(11):2223-2232. PubMed ID: 38630027
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MALDI-TOF mass spectrometry distinguishes daratumumab from M-proteins.
    Moore LM; Cho S; Thoren KL
    Clin Chim Acta; 2019 May; 492():91-94. PubMed ID: 30790545
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interference of daratumumab in monitoring multiple myeloma patients using serum immunofixation electrophoresis can be abrogated using the daratumumab IFE reflex assay (DIRA).
    van de Donk NW; Otten HG; El Haddad O; Axel A; Sasser AK; Croockewit S; Jacobs JF
    Clin Chem Lab Med; 2016 Jun; 54(6):1105-9. PubMed ID: 26812873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interference.
    McCudden C; Axel AE; Slaets D; Dejoie T; Clemens PL; Frans S; Bald J; Plesner T; Jacobs JF; van de Donk NW; Moreau P; Schecter JM; Ahmadi T; Sasser AK
    Clin Chem Lab Med; 2016 Jun; 54(6):1095-104. PubMed ID: 27028734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complete Depletion of Daratumumab Interference in Serum Samples from Plasma Cell Myeloma Patients Improves the Detection of Endogenous M-Proteins in a Preliminary Study.
    Vakili H; Koorse Germans S; Dong X; Kansagra A; Patel H; Muthukumar A; Hashim IA
    Diagnostics (Basel); 2020 Apr; 10(4):. PubMed ID: 32295157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of multiple myeloma with monoclonal antibodies and the dilemma of false positive M-spikes in peripheral blood.
    Murata K; McCash SI; Carroll B; Lesokhin AM; Hassoun H; Lendvai N; Korde NS; Mailankody S; Landau HJ; Koehne G; Chung DJ; Giralt SA; Ramanathan LV; Landgren O
    Clin Biochem; 2018 Jan; 51():66-71. PubMed ID: 27664535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pilot Verification of a Novel Approach to Remove Electrophoretic Interference of the Therapeutic Monoclonal Antibody Daratumumab.
    Baloda V; Shurin MR; Wheeler SE
    J Appl Lab Med; 2022 Jun; 7(4):910-915. PubMed ID: 35060610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. False positive results: a challenge for laboratory physicians and hematologists in treating multiple myeloma with daratumumab.
    Liang S; Feng W; Ma H; Zhang L; Jia C
    Hematology; 2022 Dec; 27(1):332-336. PubMed ID: 35255237
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identifying therapeutic monoclonal antibodies using target protein collision electrophoresis reflex assay to separate the wheat from the chaff.
    Teuwen JTJ; Ritzen LFL; Knapen-Portz YM; Ludwiczek PK; Damoiseaux JGMC; van Beers JJBC; de Boer D
    J Immunol Methods; 2023 Nov; 522():113552. PubMed ID: 37652294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An international multi-center serum protein electrophoresis accuracy and M-protein isotyping study. Part II: limit of detection and follow-up of patients with small M-proteins.
    Jacobs JFM; Turner KA; Graziani MS; Frinack JL; Ettore MW; Tate JR; Booth RA; McCudden CR; Keren DF; Delgado JC; Zemtsovskaja G; Fullinfaw RO; Caldini A; de Malmanche T; Katakouzinos K; Burke M; Palladini G; Altinier S; Zaninotto M; Righetti G; Melki MT; Bell S; Willrich MAV
    Clin Chem Lab Med; 2020 Mar; 58(4):547-559. PubMed ID: 31940285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence and Management of Therapeutic Monoclonal Antibody Interference in Monoclonal Gammopathy Monitoring.
    Liu L; Wertz WJ; Kondisko A; Shurin MR; Wheeler SE
    J Appl Lab Med; 2020 Jan; 5(1):29-40. PubMed ID: 32445341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Using MALDI-TOF mass spectrometry in peripheral blood for the follow up of newly diagnosed multiple myeloma patients treated with daratumumab-based combination therapy.
    Eveillard M; Korde N; Ciardiello A; Diamond B; Lesokhin A; Mailankody S; Smith E; Hassoun H; Hultcrantz M; Shah U; Lu S; Salcedo M; Werner K; Rispoli J; Mastey D; Landgren O; Thoren K
    Clin Chim Acta; 2021 May; 516():136-141. PubMed ID: 33545108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An up-conversion fluorescence lateral-flow immunoassay for rapid detection of Daratumumab in serum protein electrophoresis clinical samples.
    Liu Y; Tao Y; Yeung PS; Lu M; Liu J; Yu F; Shi RZ; Luo RY
    Clin Chim Acta; 2024 Jun; 559():119677. PubMed ID: 38636694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.